UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): March 11,
2020
AZURRX
BIOPHARMA, INC.
(Exact
name of Registrant as specified in its Charter)
Delaware
|
001-37853
|
46-4993860
|
(State
or Other Jurisdiction of
Incorporation
or Organization)
|
(Commission
File Number)
|
(I.R.S.
Employer
Identification
No.)
|
760 Parkside Avenue
Downstate Biotechnology Incubator,
Suite 304
Brooklyn, New
York
|
|
11226
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s telephone number, including area code:
(646) 699-7855
(Name,
address, including zip code, and telephone number, including area
code, of agent for service of process)
NOT
APPLICABLE
(Former
Name or Former Address, if Changes Since Last Report)
Check
the appropriate box below if the Form 8-K is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions):
[
] Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
[
] Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
[
] Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
[
] Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the
Act:
Title
of each class
|
Trading
Symbol(s)
|
Name of
each exchange on which registered
|
Common
Stock, par value $0.0001 per share
|
AZRX
|
Nasdaq
Capital Market
|
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (17 CFR
230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17
CFR 240.12b-2) ☒
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act ☐
Item 7.01 Regulation FD Disclosure.
On March 11, 2020, AzurRx BioPharma, Inc. (the
“Company”) provided TransChem, Inc.
(“TransChem”) with sixty (60) days prior written notice
of its intent to terminate the sublicene agreement dated January
14, 2017 between TransChem and the Company (the
“Sublicense
Agreement”). The
Sublicense Agreement and the licenses granted thereunder related to
Helicobacter pylori (“H. pylori”)
5’methylthioadenosine
nucleosidase inhibitors in preclinical
development.
The
Company is focusing its resources on the development of its lead
drug product candidate, MS1819, in Phase II clinical trials for the
treatment of exocrine pancreatic insufficiency (EPI) associated
with cystic fibrosis and chronic pancreatitis.
The information in this Current Report on Form 8-K is being
furnished and shall not be deemed "filed" for purposes of Section
18 of the Securities Exchange Act of 1934, as amended (the
"Exchange Act"), nor shall it be deemed incorporated by reference
in any filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as shall be expressly set forth by specific
reference in such a filing.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this Report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
AzurRx BioPharma, Inc.
|
|
||
|
|
|
|
|
Date:
March 16, 2020
|
By:
|
/s/
Daniel Schneiderman
|
|
|
|
|
Name: Daniel Schneiderman
|
|
|
|
|
Title: Chief FInancial Officer
|
|
|